ClinConnect ClinConnect Logo
Search / Trial NCT00437320

Comparison of Metvix Photodynamic Therapy (PDT) With Its Vehicle in the Treatment of Photoaged Skin

Launched by GALDERMA R&D · Feb 19, 2007

Trial Information

Current as of July 21, 2025

Completed

Keywords

Pdt Photoaging Galderma

ClinConnect Summary

Different application times of the study treatment were being investigated.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Male or female participants older than 30 years of age.
  • Participants with a photodamage grade of at least 4 on the Griffiths photonumeric scale (symmetrical photodamage on the two target areas)
  • Participants with mottled hyper-pigmentation on the face
  • Participants willing and capable of cooperating to the extent and degree required by the protocol
  • Participants must read the Patient Information Sheet and read and sign the Informed Consent form prior to any study related procedures.
  • Exclusion Criteria:
  • Participants who were at risk in terms of precautions, warnings, and contra-indication in the package insert for Metvix
  • Participants with suspected porphyria
  • Participants with specific wash-out period for interfering treatments
  • Participants requiring concurrent treatment that would interfere with study objectives and/or evaluations

About Galderma R&D

Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.

Locations

London, , United Kingdom

Manchester, , United Kingdom

Madrid, , Spain

Patients applied

0 patients applied

Trial Officials

CEM Griffiths

Principal Investigator

Professor

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials